Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 33Ovarian Neoplasms 9Breast Neoplasms 9Pancreatic Neoplasms 8Metastatic Castration-resistant Prostate Cancer 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Sarcoma 3Lymphoma, Non-Hodgkin 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Prostatic Neoplasms, Castration-Resistant 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hereditary Sensory and Autonomic Neuropathies 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Castration-Resistant Prostate Carcinoma 2Xanthogranuloma, Juvenile 1

Interventions

Cyclophosphamide 8pembrolizumab 6Filgrastim 5Busulfan 5fludarabine phosphate 4fludarabine 4Nivolumab 4Flow Cytometry 4Antilymphocyte Serum 4Alemtuzumab 4Tacrolimus 3Stem Cell Transplantation 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Mycophenolic Acid 3Melphalan 3Dexamethasone 3Carboplatin 3Biopsy 3Azacitidine 3valspodar 2atezolizumab 2aldesleukin 2X-Rays 2Vorinostat 2Vincristine 2Thiotepa 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × olaparib × Genitourinary × Clear all
NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

AstraZeneca

Phase 1 Completed
49 enrolled
BreastGastrointestinalGenitourinaryGynecologicLymphoid

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡